Deletion of the STOP gene, a microtubule stabilizing factor, leads only to discrete cerebral metabolic changes in mice

Journal of Neuroscience Research

Volumn 86, Issue 4, 2008, Pages 813-820

  Hanaya, Ryosuke ^a   Koning, Estelle ^a   Ferrandon, Arielle ^a   Schweitzer, Annie ^a   Andrieux, Annie ^a   Nehlig, Astrid ^a  

^a INSERM   (France)

Author keywords

Cerebral glucose metabolism; Cytoskeleton; Microtubules; Schizophrenia; STOP protein; Transgenic mice

Indexed keywords

CARBON 14; DEOXYGLUCOSE; GLUCOSE; MICROTUBULE PROTEIN; STABLE TUBULE ONLY POLYPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CATHETERIZATION; ARTICLE; AUDITORY SYSTEM; AUTORADIOGRAPHY; BRAIN METABOLISM; BRAIN REGION; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DORSAL RAPHE NUCLEUS; GENE; GENE DELETION; GLUCOSE BRAIN LEVEL; GLUCOSE UTILIZATION; HETEROZYGOSITY; HOMOZYGOSITY; HYPOTHALAMUS; MALE; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; OLFACTORY CORTEX; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; QUANTITATIVE ANALYSIS; SCHIZOPHRENIA; STOP GENE; SUBSTANTIA NIGRA; SYNAPSE; VEIN CATHETERIZATION; VENTRAL TEGMENTUM; WILD TYPE;

EID: 40549126320     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21550     Document Type: Article

References (71)

1. Abi‐Dargham A, Gil R, Krystal J, Baldwin BM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M. 1998. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155: 761–767.
2. Aleman A, Bocker KB, Hijman R, de Haan EH, Kahn RS. 2003. Cognitive basis of hallucinations in schizophrenia: role of top‐down information processing. Schizophr Res 64: 175–185.
3. Andreasen NC, Black DW. 1991. Introductory Textbook of Psychiatry. Washington, DC: American Psychiatry Press.
4. Andrieux A, Salin PA, Vernet M, Kujala P, Baratier J, Gory‐Fauré S, Bosc C, Pointu H, Proietto D, Schweitzer A, Denarier E, Klumperman J, Job D. 2002. The suppression of brain cold‐stable microtubules in mice induces synaptic defects associated with neuroleptic‐sensitive behavioral disorders. Genes Dev 16: 2350–2364.
5. Andrieux A, Salin P, Schweitzer A, Begou M, Pachoud B, Brun P, Gory‐Faure S, Kujala P, Suaud‐Chagny MF, Höfle G, Job D. 2006. Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia. Biol Psychiatry 60: 1224–1230.
6. Baas PW, Pienkowski TP, Cimbalnik KA, Toyama K, Bakalis S, Ahmad FJ, Kosik KS. 1994. Tau confers drug stability but not cold stability to microtubules in living cells. J Cell Sci 107: 135–43.
7. Baratier J, Peris L, Brocard J, Gory‐Faure S, Dufour F, Bosc C, Fourest‐Lieuvin A, Blanchoin L, Salin P, Job D, Andrieux A. 2006. Phosphorylation of microtubule‐associated protein STOP by calmodulin kinase II. J Biol Chem 281: 19561–19569.
8. Blackwood D, Clair DS, Muir W, Duffy J. 1991. Auditory p300 and eye tracking dysfunction in schizophrenic pedigrees. Arch Gen Psychiatry 48: 899–909.
9. Bosc C, Andrieux A, Job D. 2003. STOP proteins. Biochemistry 42: 12125–12132.
10. Bosc C, Cronk JD, Pirollet F, Watterson DM, Haiech J, Job D, Margolis RL. 1996. Cloning, expression, and properties of the microtubule‐stabilizing protein STOP. Proc Natl Acad Sci U S A 93: 2125–2130.
11. Bouilleret V, Boyet S, Marescaux C, Nehlig A. 2000. Mapping of the progressive metabolic changes occurring during the development of hippocampal sclerosis in a model of mesial temporal lobe epilepsy. Brain Res 852: 255–262.
12. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D. 1997. Schizophrenia is associated with elevated amphetamine‐induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 94: 2569–2574.
13. Brenner E, Schweitzer A, Andrieux A, Sonnewald U, Nehlig A. 2007. Confirmation of hypoglutamatergic activity in the STOP KO mouse: a potential model for chronic untreated schizophrenia. J Neurosci Res, Feb 15; [Epub ahead of print].
14. Brun P, Bégou M, Andrieux A, Mouly‐Badina L, Clerget M, Schweitzer A, Scarna H, Renaud B, Job D, Suaud‐Chagny MF. 2005. Dopaminergic transmission in STOP null mice. J Neurochem 94: 63–73.
15. Clark C, Kopala L, Li DK, Hurwitz T. 2001. Regional cerebral glucose metabolism in never‐medicated patients with schizophrenia. Can J Psychiatry 46: 340–345.
16. Clementz BA, Geyer MA, Braff DL. 1998. Poor P50 suppression among schizophrenia patients and their first‐degree biological relatives. Am J Psychiatry 155: 1691–1694.
17. Couégnas A, Schweitzer A, Andrieux A, Ghandour MS, Boehm N. 2007. Expression pattern of STOP lacZ reporter gene in adult and developing mouse brain. J Neurosci Res 85: 1515–1527.
18. Denarier E, Fourest‐Lieuvin A, Bosc C, Pirollet F, Chapel A, Margolis RL, Job D. 1998. Nonneuronal isoforms of STOP protein are responsible for microtubule cold stability in mammalian fibroblasts. Proc Natl Acad Sci U S A 95: 6055–6060.
19. Dustin P. 1984. Microtubules. 2nd ed. Berlin: Springer Verlag.
20. Eastwood SL, Lyon L, George L, Andrieux A, Job D, Harrison PJ. 2007. Altered expression of synaptic protein mRNAs in STOP (MAP6) mutant mice. J Psychopharmacol 21: 635–644.
21. Fradley RA, O'Meara GF, Newman RJ, Andrieux A, Job D, Reynolds DS. 2005. STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav Brain Res 163: 257–264.
22. Frankle WG, Lerma J, Laruelle M. 2003. The synaptic hypothesis of schizophrenia. Neuron 39: 205–216.
23. Franklin KBJ, Paxinos G. 1997. The Mouse Brain in Stereotaxic Coordinates. San Diego, CA: Academic Press.
24. Galiano MR, Bosc C, Schweitzer A, Andrieux A, Job D, Hallak ME. 2004. Astrocytes and oligodendrocytes express different STOP protein isoforms. J Neurosci Res 78: 329–337.
25. Geraud G, Arne‐Bes MC, Guell A, Bes A. 1987. Reversibility of hemodynamic hypofrontality in schizophrenia. J Cereb Blood Flow Metab 7: 9–12.
26. Ginovart N, Farde L, Halldin C, Swahn CG. 1999. Changes in striatal D2‐receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates. Synapse 31: 154–162.
27. Goff DC, Coyle JT. 2001. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158: 1367–1377.
28. Gory‐Faure S, Windscheid V, Bosc C, Peris L, Proietto D, Franck R, Denarier E, Job D, Andrieux A. 2006. STOP‐like protein 21 is a novel member of the STOP family, revealing a Golgi localization of STOP proteins. J Biol Chem 281: 28387–28396.
29. Grace AA. 1991. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41: 1–24.
30. Guillaud L, Bosc C, Fourest‐Lieuvin A, Denarier E, Pirollet F, Lafanechere L, Job D. 1998. STOP proteins are responsible for the high degree of microtubule stabilization observed in neuronal cells. J Cell Biol 142: 167–179.
31. Guyton AC. 1989. Anatomie et Physiologie du Système Nerveux Central. Montréal/Paris: Décarie/Vigot.
32. Horton AC, Ehlers MD. 2004. Secretory trafficking in neuronal dendrites. Nat Cell Biol 6: 585–591.
33. Hubl D, Koenig T, Strik W, Federspiel A, Kreis R, Boesch C, Maier SE, Schroth G, Lovblad K, Dierks T. 2004. Pathways that make voices: white matter changes in auditory hallucinations. Arch Gen Psychiatry 61: 658–668.
34. Hudry J, Saoud M, D'Amato T, Daléry J, Royet JP. 2002. Ratings of different olfactory judgements in schizophrenia. Chem Senses 27: 407–416.
35. Jay TM, Jouvet M, des Rosiers MH. 1985. Local cerebral glucose utilization in the free moving mouse: a comparison during two stages of the activity‐rest cycle. Brain Res 342: 297–306.
36. Kaplan RD, Szechtman H, Franco S, Szechtman B, Nahmias C, Garnett ES, List S, Cleghorn JM. 1993. Three clinical syndromes of schizophrenia in untreated subjects: relation to brain glucose activity measured by positron emission tomography (PET). Schizophr Res 11: 47–54.
37. Kapur S, Remington G. 1996. Serotonin‐dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153: 466–476.
38. Kerwin RW. 1993. Glutamate receptors, microtubule associated proteins and developmental anomaly in schizophrenia: an hypothesis. Psychol Med 23: 547–551.
39. Kolman A. 2004. BMS‐310705 Bristol‐Myers Squibb/GBF. Curr Opin Investig Drugs 5: 1292–1297.
40. Kopala LC, Good KP, Morrison K, Bassett AS, Alda M, Honer WG. 2001. Impaired olfactory identification in relatives of patients with familial schizophrenia. Am J Psychiatry 158: 1286–1290.
41. Lahti AC, Weiler MA, Holcomb HH, Tamminga CA, Carpenter WT, McMahon R. 2006. Correlations between rCBF and symptoms in two independent cohorts of drug‐free patients with schizophrenia. Neuropsychopharmacology 31: 221–230.
42. Laruelle M, Abi‐Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB. 1996. Single photon emission computerized tomography imaging in amphetamine‐induced dopamine release in drug‐free schizophrenic subjects. Proc Natl Acad Sci U S A 93: 9235–9240.
43. Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiak RS. 1992. Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 160: 179–186.
44. Margolis RL, Wilson L. 1978. Opposite end assembly and disassembly of microtubules at steady state in vitro. Cell 13: 1–8.
45. Mathalon DH, Ford JM, Pfefferbaum A. 2000. Trait and state aspects of P300 amplitude reduction in schizophrenia: a retrospective longitudinal study. Biol Psychiatry 47: 434–449.
46. McCurdy RD, Feron F, Perry C, Chant DC, McLean D, Matigian N, Hayward NK, McGrath JJ, Mackay‐Sim A. 2006. Cell cycle alterations in biopsied olfactory neuroepithelium in schizophrenia and bipolar I disorder using cell culture and gene expression analyses. Schizophr Res 82: 163–173.
47. Min SK, An SK, Jon DI, Lee JD. 1999. Positive and negative symptoms and regional cerebral perfusion in antipsychotic‐naive schizophrenic patients: a high‐resolution SPECT study. Psychiatry Res 90: 159–168.
48. Mitchison T, Kirschner M. 1984. Dynamic instability of microtubule growth. Nature 312: 237–242.
49. Moberg PJ, Agrin R, Gur RE, Gur RC, Turetsky BI, Doty RL. 1999. Olfactory dysfunction in schizophrenia: a qualitative and quantitative review. Neuropsychopharmacology 21: 325–340.
50. Monti JM, Monti D. 2004. Sleep in schizophrenia patients and the effects of antipsychotic drugs. Sleep Med Rev 8: 133–148.
51. Murphy DD, Cole NB, Greenberger V, Segal M. 1998. Estradiol increases dendritic spine density by reducing GABA neurotransmission in hippocampal neurons. J Neurosci 18: 2550–2559.
52. Nehlig A, Lucignani G, Kadekaro M, Porrino LJ, Sokoloff L. 1984. Effects of acute administration of caffeine on local cerebral glucose utilization in the rat. Eur J Pharmacol 101: 91–100.
53. Nehlig A, Porrino LJ, Crane AM, Sokoloff L. 1985. Local cerebral glucose utilization in normal female rats: Variations during the estrous cycle and comparison with males. J Cereb Blood Flow Metab 5: 393–400.
54. Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN. 1993. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 19: 351–86.
55. Rioux L, Ruscheinsky D, Arnold SE. 2004. Microtubule‐associated protein MAP2 expression in olfactory bulb in schizophrenia. Psychiatry Res 128: 1–7.
56. Rupp CI, Fleischhacker WW, Kemmler G, Kremser C, Bilder RM, Mechtcheriakov S, Szeszko PR, Walch T, Scholtz AW, Klimbacher M, Maier C, Albrecht G, Lechner‐Schoner T, Felber S, Hinterhuber H. 2005. Olfactory functions and volumetric measures of orbitofrontal and limbic regions in schizophrenia. Schizophr Res 74: 149–161.
57. Sabri O, Erkwoh R, Schreckenberger M, Cremerius U, Schulz G, Dickmann C, Kaiser HJ, Steinmeyer EM, Sass H, Buell U. 1997. Regional cerebral blood flow and negative/positive symptoms in 24 drug‐naive schizophrenics. J Nucl Med 38: 181–188.
58. Sallanon M, Sakai K, Denoyer M, Jouvet M. 1989. Long lasting insomnia induced by preoptic neuron lesions and its transient reversal by muscimol injection into the posterior hypothalamus. Neuroscience 32: 669–683.
59. Shimizu H, Iwayama Y, Yamada K, Toyota T, Minabe Y, Nakamura K, Nakajima M, Hattori E, Mori N, Osumi N, Yoshikawa T. 2006. Genetic and expression analyses of the STOP (MAP6) gene in schizophrenia. Schizophr Res 84: 244–252.
60. Siegel C, Waldo M, Mizner G, Adler LE, Freeman R. 1984. Deficits in sensory gating in schizophrenic patients and their relatives. Evidence obtained with auditory evoked responses. Arch Gen Psychiatry 41: 607–612.
61. Spitzer RL, Gibbon M, Skodol AE, Williams JBW, First MB. 1994. DSM‐IV Casebook. Washington, DC: American Psychiatry Press.
62. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M. 1977. The [ 14 C]deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure and normal values in the conscious and anesthetized albino rat. J Neurochem 28: 897–916.
63. Szymusiak R, Alam N, Steininger TL, McGinty D. 1998. Sleep‐waking discharge patterns of ventrolateral preoptic/hypothalamic neurons in rats. Brain Res 803: 178–188.
64. Szymusiak R, Satinoff E. 1984. Ambient temperature‐dependence of sleep disturbances produced by basal forebrain damage in rats. Brain Res Bull 12: 295–305.
65. Ticho SR, Radulovacki M. 1991. Role of adenosine in sleep and temperature regulation in the preoptic area of rats. Pharmacol Biochem Behav 40: 33–40.
66. Ugur T, Weisbrod M, Franzek E, Pfuller U, Sauer H. 2005. Olfactory impairment in monozygotic twins discordant for schizophrenia. Eur Arch Psychiatry Clin Neurosci 255: 94–98.
67. Wang H, Wang Z, Wang S, Li M, Nan L, Rhie JK, Covey JM, Zhang R, Hill DL. 2005. Preclinical pharmacology of epothilone D, a novel tubulin‐stabilizing antitumor agent. Cancer Chemother Pharmacol 56: 255–260.
68. Weinberger DR, Berman KF, Zec RF. 1986. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch Gen Psychiatry 43: 114–124.
69. Wolkin A, Sanfilipo M, Wolf AP, Angrist B, Brodie JD, Rotrosen J. 1992. Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry 49: 959–965.
70. Wong AHC, Van Tol HHM. 2003. Schizophrenia: from phenomenology to neurobiology. Neurosci Biobehav Rev 27: 269–306.
71. Yuasa S, Kurachi M, Suzuki M, Kadono Y, Matsui M, Saitoh O, Seto H. 1995. Clinical symptoms and regional cerebral blood flow in schizophrenia. Eur Arch Psychiatry Clin. Neurosci 246: 7–12.